Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can software help doctors spot a hidden inherited cholesterol threat?

NCT ID NCT03989167

Diagnosis Sponsor: University Hospital, Linkoeping Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 14, 2026 · Last updated Oct 15, 2026 · Updated 1 time

Summary

Familial hypercholesterolemia is an inherited condition that causes very high cholesterol and early heart disease, and many people who have it go undiagnosed. This cluster randomized trial in Swedish primary care tests a computer-based clinical decision support tool that flags patients with high total cholesterol or LDL-C who may be at risk. Researchers compare how many patients receive a familial hypercholesterolemia diagnosis in clinics that use the tool versus those that do not, with the main measure taken 36 months after the study begins.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a computer-based clinical decision support tool
What this could lead to
If the tool works, it could help primary care doctors find more people with familial hypercholesterolemia, a common inherited condition that raises heart attack risk from a young age.
What could go wrong
The tool may not change how often doctors diagnose the condition, and any improvement could depend on how well clinics use it. This study measures diagnoses, not whether early treatment prevents heart attacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

472,029 people

The number who actually took part.

Started

Dec 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Primary care centers in the county of Östergötland. Exclusion Criteria * Primary care centers not using the Cambio Cosmic Electronic Health Record System.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical decision support are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial hypercholesterolemia hypercholesterolemia, familial, 1 Hyperlipoproteinemia Type II

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical decision support Hypercholesterolemia, familial

Contacts and locations

Locations

  • Universitetssjukhuset i Linköping

    Linköping, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.